{
    "pmcid": "PMC5749368",
    "title": "Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism",
    "study_parameters": {
        "summary": {
            "content": "The study aimed to determine if genetic variants in the *CYP2C9* and *VKORC1* genes could identify patients with venous thromboembolism (VTE) at increased risk of bleeding when treated with warfarin. Conducted as a subanalysis of the Hokusai VTE trial, it involved genotyping patients to classify them into warfarin sensitivity types (normal, sensitive, and highly sensitive). The results showed that sensitive and highly sensitive responders had a higher risk of bleeding, required lower warfarin doses, and spent more time overanticoagulated compared to normal responders, highlighting the potential utility of genetic testing in managing warfarin therapy.",
            "citations": [
                "The *CYP2C9*CYP2C9 and *VKORC1*VKORC1 polymorphisms were in Hardy-Weinberg equilibrium for all three race groups examined (ie, Caucasians, African Americans and East Asians), and the observed allele frequencies within each race group were consistent with previously published findings (online [supplementary table 1](#SP1)supplementary table 1).[11](#R11)^11^11\n\n[heartjnl-2016-310901supp001.pdf](/articles/instance/5749368/bin/heartjnl-2016-310901supp001.pdf)heartjnl-2016-310901supp001.pdf^ (231.1KB, pdf) ^ (231.1KB, pdf)\n\nOut of the 8292 patients in Hokusai VTE, 3956 (47.7%) participants (1978 from each treatment group) received \u22651 dose of the study drug, consented to be included in the pharmacogenetic analysis and provided a pharmacogenetic sample and were therefore included in the present analysis.",
                "As a class, compared with VKAs, these agents are at least as efficacious, are associated with a lower risk of major bleeding, have more predictable pharmacodynamics and require less frequent laboratory monitoring in individuals with VTE.[5](#R5)^5^5\n\nThe individual response to VKAs, such as warfarin, is influenced by demographics, clinical characteristics and genetic factors.[3 6\u20139](#R3)^3 6\u20139^3 6\u20139 Genetic factors influencing the response to VKAs include polymorphisms in the vitamin K epoxide reductase (*VKORC1*VKORC1) and cytochrome P450 2C9 (*CYP2C9*CYP2C9) genes.[6 8\u201310](#R6)^6 8\u201310^6 8\u201310 The *CYP2C9*CYP2C9 alleles that are the most associated with increased warfarin sensitivity are more common in individuals of European descent compared with African or Asian descent.[11](#R11)^11^11 Conversely, the prevalence of the *VKORC1*VKORC1 allele that is associated with greatest increase in warfarin sensitivity is the highest in individuals of Asian descent.[11 12](#R11)^11 12^11 12 Together, the polymorphisms in these two genes account for up to 50% of the variability in warfarin dose in patients of European descent.[8](#R8)^8^8\n\nIn a recent subanalysis of the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation\u2013Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) study, a large double-blind, double-dummy, randomised study comparing edoxaban to warfarin for the prevention of stroke and systemic embolic events in patients with atrial fibrillation (AF), patients randomised to receive warfarin and classified as sensitive or highly sensitive warfarin responders, based on *CYP2C9*CYP2C9 and *VKORC1*VKORC1 genotypes, experienced more warfarin-associated bleeding and spent more time overanticoagulated relative to normal responders.[13](#R13)^13^13 This effect was observed during the first 90 days of warfarin therapy, but was not present afterwards, suggesting that the effect of genetics on warfarin-induced bleeding risk is strongest during the initiation of therapy when the warfarin dose is still being optimised.",
                "All patients who received at least one dose of the study drug consented to be included in the pharmacogenetic analysis and provided a pharmacogenetic sample were included in the analysis."
            ]
        },
        "study_type": {
            "content": "Clinical trial, prospective, replication study",
            "citations": [
                "In the Hokusai VTE trial, the overall time spent in therapeutic range was 63.5%,[14](#R14)^14^14 which is higher than what is typically reported in registries of clinical practice but is similar to what was reported in the ENGAGE AF-TIMI 48 study.[16\u201318](#R16)^16\u201318^16\u201318 It is therefore possible that the effect of genetic variants may be more pronounced outside of the clinical trial environment and that the rigour required in registrational clinical trials leads to a mitigation of the risks associated with the polymorphism through the increase in laboratory monitoring.",
                "Similar to the ENGAGE AF-TIMI 48 study, DNA samples were collected in the Hokusai-venous thromboembolism (Hokusai VTE) trial, allowing for a comparison of clinical outcomes by genotype.",
                "In addition, the study was underpowered for the three-bin analysis and the results of the exploratory two-bin analysis should only be considered hypothesis generating."
            ]
        },
        "participant_info": {
            "content": "The study included 3956 participants from the Hokusai VTE trial, with 1978 patients in each treatment group (warfarin and edoxaban). The average age of participants was approximately 55-56 years, with a slight majority being male (60.4% in normal responders, 58.7% in sensitive responders, and 53.4% in highly sensitive responders). Ethnically, the majority were Caucasian (82.6% of normal responders, 82.1% of sensitive responders, and 82.4% of highly sensitive responders), with smaller proportions of Black and Asian participants. A notable finding was that a larger proportion of sensitive and highly sensitive responders were of Asian ancestry compared to normal responders, reflecting known genetic differences in warfarin sensitivity. Baseline characteristics such as weight, BMI, and creatinine clearance were similar across genotype categories, and the study excluded patients with contraindications to heparin or warfarin, those with certain pre-existing conditions, and those on specific medications.",
            "citations": [
                "As a class, compared with VKAs, these agents are at least as efficacious, are associated with a lower risk of major bleeding, have more predictable pharmacodynamics and require less frequent laboratory monitoring in individuals with VTE.[5](#R5)^5^5\n\nThe individual response to VKAs, such as warfarin, is influenced by demographics, clinical characteristics and genetic factors.[3 6\u20139](#R3)^3 6\u20139^3 6\u20139 Genetic factors influencing the response to VKAs include polymorphisms in the vitamin K epoxide reductase (*VKORC1*VKORC1) and cytochrome P450 2C9 (*CYP2C9*CYP2C9) genes.[6 8\u201310](#R6)^6 8\u201310^6 8\u201310 The *CYP2C9*CYP2C9 alleles that are the most associated with increased warfarin sensitivity are more common in individuals of European descent compared with African or Asian descent.[11](#R11)^11^11 Conversely, the prevalence of the *VKORC1*VKORC1 allele that is associated with greatest increase in warfarin sensitivity is the highest in individuals of Asian descent.[11 12](#R11)^11 12^11 12 Together, the polymorphisms in these two genes account for up to 50% of the variability in warfarin dose in patients of European descent.[8](#R8)^8^8\n\nIn a recent subanalysis of the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation\u2013Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) study, a large double-blind, double-dummy, randomised study comparing edoxaban to warfarin for the prevention of stroke and systemic embolic events in patients with atrial fibrillation (AF), patients randomised to receive warfarin and classified as sensitive or highly sensitive warfarin responders, based on *CYP2C9*CYP2C9 and *VKORC1*VKORC1 genotypes, experienced more warfarin-associated bleeding and spent more time overanticoagulated relative to normal responders.[13](#R13)^13^13 This effect was observed during the first 90 days of warfarin therapy, but was not present afterwards, suggesting that the effect of genetics on warfarin-induced bleeding risk is strongest during the initiation of therapy when the warfarin dose is still being optimised.",
                "Demographics and baseline clinical characteristics across genotype bins\n\n|  | Normal responders (n=2459) | Sensitive responders (n=1366) | Highly sensitive responders (n=131) |\n| - | -------------------------- | ----------------------------- | ----------------------------------- |\n| Age (year), mean\u00b1SD | 55.3\u00b115.92 | 56.5\u00b115.58 | 56.3\u00b117.47 |\n| Male, n (%) | 1486 (60.4) | 802 (58.7) | 70 (53.4) |\n| Race, n (%) |  |  |  |\n| Caucasian | 2031 (82.6) | 1122 (82.1) | 108 (82.4) |\n| Black | 147 (6.0) | 5 (0.4) | 0 |\n| Asian | 113 (4.6) | 157 (11.5) | 15 (11.5) |\n| Native Hawaiian/Pacific Islander | 0 | 1 (<0.1) | 0 |\n| Other | 164 (6.7) | 77 (5.6) | 7 (5.3) |\n| Weight (kg), mean\u00b1SD | 85.5\u00b119.42 | 83.7\u00b119.25 | 83.2\u00b119.91 |\n| BMI (kg/m2), mean\u00b1SD | 28.8\u00b15.95 | 28.3\u00b15.45 | 28.5\u00b16.40 |\n| Creatinine clearance (mL/min), mean\u00b1SD | 108.5\u00b140.14 | 106.2\u00b139.69 | 103.8\u00b140.62 |\n| Edoxaban dose adjusted at randomisation, n (%)* | 295 (12.0) | 207 (15.2) | 17 (13.0) |\n### Duration of heparin dose, final warfarin dose, TTR and bleeding risk with warfarin\n\nIn warfarin-treated patients, but not edoxaban-treated patients, as genetically defined warfarin sensitivity increased, heparin therapy was discontinued sooner (global p<0.001; p<0.0001 vs normal responders for both sensitive and highly sensitive responders) and the final mean weekly warfarin doses decreased (global p<0.001; p<0.0001 vs normal responders for both sensitive and highly sensitive responders) ([figure 2A and B](#F2)figure 2A and B).",
                "The trial demonstrated that, following initial parenteral anticoagulant therapy, edoxaban was non-inferior to warfarin for the treatment of VTE and the prevention of recurrent VTE and was also associated with significantly fewer bleeding events in patients with VTE.[14](#R14)^14^14 The present analysis was designed to replicate the ENGAGE AF-TIMI 48 findings and examine whether the previous results could be extended to patients with VTE."
            ]
        },
        "study_design": {
            "content": "The study was a pharmacogenetic subanalysis of the Hokusai-venous thromboembolism (Hokusai VTE) trial, which was a randomized, multinational, double-blind, non-inferiority trial comparing the safety and efficacy of edoxaban versus warfarin in patients with acute, symptomatic venous thromboembolism (VTE) initially treated with heparin. The trial enrolled 8,292 patients from 439 centers worldwide, but this subanalysis included 3,956 patients who received at least one dose of the study drug, consented to the pharmacogenetic analysis, and provided a genetic sample. Patients were genotyped for variants in the CYP2C9 and VKORC1 genes and categorized into three warfarin sensitivity types: normal, sensitive, and highly sensitive responders. The study aimed to investigate whether these genetic variants could identify patients at increased risk of bleeding with warfarin.",
            "citations": [
                "The trial demonstrated that, following initial parenteral anticoagulant therapy, edoxaban was non-inferior to warfarin for the treatment of VTE and the prevention of recurrent VTE and was also associated with significantly fewer bleeding events in patients with VTE.[14](#R14)^14^14 The present analysis was designed to replicate the ENGAGE AF-TIMI 48 findings and examine whether the previous results could be extended to patients with VTE.",
                "Kaplan-Meier methodology was used to assess the time-to-bleeding event curves for patients treated with warfarin during the first 90 days of treatment; p values are based on the Cox proportional hazards model with genotype of responder as covariate.",
                "**Methods:** \nHokusai-venous thromboembolism (Hokusai VTE), a randomised, multinational, double-blind, non-inferiority trial, evaluated the safety and efficacy of edoxaban versus warfarin in patients with VTE initially treated with heparin."
            ]
        },
        "study_results": {
            "content": "The study investigated the impact of genetic variants on bleeding risk in patients with venous thromboembolism (VTE) treated with warfarin. It found that patients with certain *CYP2C9* and *VKORC1* genotypes, classified as sensitive or highly sensitive responders, had an increased risk of bleeding compared to normal responders. Specifically, sensitive responders had a hazard ratio (HR) of 1.38 (95% CI 1.11 to 1.71, p=0.0035) and highly sensitive responders had an HR of 1.79 (95% CI 1.09 to 2.99, p=0.0252) for bleeding events. These patients also required lower warfarin doses and spent more time overanticoagulated. The study suggests that genetic testing could help identify patients at higher risk of bleeding when treated with warfarin.",
            "citations": [
                "The trial demonstrated that, following initial parenteral anticoagulant therapy, edoxaban was non-inferior to warfarin for the treatment of VTE and the prevention of recurrent VTE and was also associated with significantly fewer bleeding events in patients with VTE.[14](#R14)^14^14 The present analysis was designed to replicate the ENGAGE AF-TIMI 48 findings and examine whether the previous results could be extended to patients with VTE.",
                "These results confirmed that for stroke prevention in patients with AF, compared with warfarin, edoxaban was associated with a greater reduction in bleeding risk in sensitive and highly sensitive responders than in normal responders in the first 90 days.",
                "All statistical significant conclusions are based on two-sided tests with a significance level of 0.05."
            ]
        },
        "allele_frequency": {
            "content": "The study reports that the allele frequencies of the *CYP2C9* and *VKORC1* polymorphisms were consistent with previously published findings and were in Hardy-Weinberg equilibrium across the examined racial groups, which included Caucasians, African Americans, and East Asians. The observed allele frequencies within each race group aligned with known data, indicating that the distribution of these genetic variants in the study population was representative of broader population trends. However, specific numerical allele frequencies for the variants in the study cohorts are not detailed in the provided text.",
            "citations": [
                "As a class, compared with VKAs, these agents are at least as efficacious, are associated with a lower risk of major bleeding, have more predictable pharmacodynamics and require less frequent laboratory monitoring in individuals with VTE.[5](#R5)^5^5\n\nThe individual response to VKAs, such as warfarin, is influenced by demographics, clinical characteristics and genetic factors.[3 6\u20139](#R3)^3 6\u20139^3 6\u20139 Genetic factors influencing the response to VKAs include polymorphisms in the vitamin K epoxide reductase (*VKORC1*VKORC1) and cytochrome P450 2C9 (*CYP2C9*CYP2C9) genes.[6 8\u201310](#R6)^6 8\u201310^6 8\u201310 The *CYP2C9*CYP2C9 alleles that are the most associated with increased warfarin sensitivity are more common in individuals of European descent compared with African or Asian descent.[11](#R11)^11^11 Conversely, the prevalence of the *VKORC1*VKORC1 allele that is associated with greatest increase in warfarin sensitivity is the highest in individuals of Asian descent.[11 12](#R11)^11 12^11 12 Together, the polymorphisms in these two genes account for up to 50% of the variability in warfarin dose in patients of European descent.[8](#R8)^8^8\n\nIn a recent subanalysis of the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation\u2013Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) study, a large double-blind, double-dummy, randomised study comparing edoxaban to warfarin for the prevention of stroke and systemic embolic events in patients with atrial fibrillation (AF), patients randomised to receive warfarin and classified as sensitive or highly sensitive warfarin responders, based on *CYP2C9*CYP2C9 and *VKORC1*VKORC1 genotypes, experienced more warfarin-associated bleeding and spent more time overanticoagulated relative to normal responders.[13](#R13)^13^13 This effect was observed during the first 90 days of warfarin therapy, but was not present afterwards, suggesting that the effect of genetics on warfarin-induced bleeding risk is strongest during the initiation of therapy when the warfarin dose is still being optimised.",
                "In this subanalysis of Hokusai VTE, patients genotyped for variants in CYP2C9 and VKORC1 genes were divided into three warfarin sensitivity types (normal, sensitive and highly sensitive) based on their genotypes.",
                "The *CYP2C9*CYP2C9 and *VKORC1*VKORC1 polymorphisms were in Hardy-Weinberg equilibrium for all three race groups examined (ie, Caucasians, African Americans and East Asians), and the observed allele frequencies within each race group were consistent with previously published findings (online [supplementary table 1](#SP1)supplementary table 1).[11](#R11)^11^11\n\n[heartjnl-2016-310901supp001.pdf](/articles/instance/5749368/bin/heartjnl-2016-310901supp001.pdf)heartjnl-2016-310901supp001.pdf^ (231.1KB, pdf) ^ (231.1KB, pdf)\n\nOut of the 8292 patients in Hokusai VTE, 3956 (47.7%) participants (1978 from each treatment group) received \u22651 dose of the study drug, consented to be included in the pharmacogenetic analysis and provided a pharmacogenetic sample and were therefore included in the present analysis."
            ]
        },
        "additional_resource_links": [
            "The study provides the following additional resources or links related to its design and execution:",
            "1. **Trial Registration Number**: [NCT00986154](https://clinicaltrials.gov/ct2/show/NCT00986154) - This link leads to the ClinicalTrials.gov page for the Hokusai VTE trial, providing detailed information about the study's design, objectives, and methodology.",
            "2. **PDF of the Article**: [https://pmc.ncbi.nlm.nih.gov/articles/PMC5749368/pdf/heartjnl-2016-310901.pdf](https://pmc.ncbi.nlm.nih.gov/articles/PMC5749368/pdf/heartjnl-2016-310901.pdf) - This link provides access to the full PDF version of the article.",
            "3. **Supplementary Materials**: [heartjnl-2016-310901supp001.pdf](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5749368/bin/heartjnl-2016-310901supp001.pdf) - This PDF contains supplementary materials related to the study, such as additional data tables or figures.",
            "These resources provide further insights into the study's methodology and findings."
        ]
    },
    "annotations": {
        "relationships": [
            {
                "gene": "CYP2C9",
                "polymorphism": "*2 (rs1799853), *3 (rs1057910)",
                "relationship_effect": "CYP2C9 variants, in combination with VKORC1, define warfarin sensitivity types (normal, sensitive, highly sensitive). Increased sensitivity is associated with lower final weekly warfarin dose, earlier discontinuation of heparin, more time overanticoagulated, and increased bleeding risk with warfarin.",
                "p_value": "p<0.001 for decreased warfarin dose and earlier heparin discontinuation; p<0.001 for more time overanticoagulated; HR for bleeding: sensitive responders 1.38 (95% CI 1.11\u20131.71), p=0.0035; highly sensitive responders 1.79 (1.09\u20132.99), p=0.0252",
                "citations": [
                    "In this subanalysis of Hokusai VTE, patients genotyped for variants in CYP2C9 and VKORC1 genes were divided into three warfarin sensitivity types (normal, sensitive and highly sensitive) based on their genotypes.",
                    "As a class, compared with VKAs, these agents are at least as efficacious, are associated with a lower risk of major bleeding, have more predictable pharmacodynamics and require less frequent laboratory monitoring in individuals with VTE.[5](#R5)^5^5\n\nThe individual response to VKAs, such as warfarin, is influenced by demographics, clinical characteristics and genetic factors.[3 6\u20139](#R3)^3 6\u20139^3 6\u20139 Genetic factors influencing the response to VKAs include polymorphisms in the vitamin K epoxide reductase (*VKORC1*VKORC1) and cytochrome P450 2C9 (*CYP2C9*CYP2C9) genes.[6 8\u201310](#R6)^6 8\u201310^6 8\u201310 The *CYP2C9*CYP2C9 alleles that are the most associated with increased warfarin sensitivity are more common in individuals of European descent compared with African or Asian descent.[11](#R11)^11^11 Conversely, the prevalence of the *VKORC1*VKORC1 allele that is associated with greatest increase in warfarin sensitivity is the highest in individuals of Asian descent.[11 12](#R11)^11 12^11 12 Together, the polymorphisms in these two genes account for up to 50% of the variability in warfarin dose in patients of European descent.[8](#R8)^8^8\n\nIn a recent subanalysis of the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation\u2013Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) study, a large double-blind, double-dummy, randomised study comparing edoxaban to warfarin for the prevention of stroke and systemic embolic events in patients with atrial fibrillation (AF), patients randomised to receive warfarin and classified as sensitive or highly sensitive warfarin responders, based on *CYP2C9*CYP2C9 and *VKORC1*VKORC1 genotypes, experienced more warfarin-associated bleeding and spent more time overanticoagulated relative to normal responders.[13](#R13)^13^13 This effect was observed during the first 90 days of warfarin therapy, but was not present afterwards, suggesting that the effect of genetics on warfarin-induced bleeding risk is strongest during the initiation of therapy when the warfarin dose is still being optimised.",
                    "The genotyping assay was previously validated as part of the ENGAGE AF-TIMI 48 pharmacogenetic analysis.[13](#R13)^13^13\n\nOn the basis of the *VKORC1*VKORC1 and *CYP2C9*CYP2C9 genotypes, patients were divided into three warfarin sensitivity types ([figure 1](#F1)figure 1), normal responders, sensitive responders and highly sensitive responders, that correspond with the US Food and Drug Administration (FDA)\u2019s categories for warfarin response included in the warfarin label.[15](#R15)^15^15 In addition, because the total number of patients included in this analysis was substantially smaller than in the ENGAGE AF-TIMI 48 pharmacogenetic analysis (3956 vs 14 348),[13](#R13)^13^13 exploratory analyses were also conducted using a two-bin system in which sensitive and highly sensitive responders were pooled together (ie, pooled sensitive responders) and compared with normal responders to increase statistical power ([figure 1](#F1)figure 1)."
                ]
            },
            {
                "gene": "VKORC1",
                "polymorphism": "-1639 G>A (rs9923231)",
                "relationship_effect": "VKORC1 variant, in combination with CYP2C9, defines warfarin sensitivity types (normal, sensitive, highly sensitive). Increased sensitivity is associated with lower final weekly warfarin dose, earlier discontinuation of heparin, more time overanticoagulated, and increased bleeding risk with warfarin.",
                "p_value": "p<0.001 for decreased warfarin dose and earlier heparin discontinuation; p<0.001 for more time overanticoagulated; HR for bleeding: sensitive responders 1.38 (95% CI 1.11\u20131.71), p=0.0035; highly sensitive responders 1.79 (1.09\u20132.99), p=0.0252",
                "citations": [
                    "The *CYP2C9*CYP2C9 and *VKORC1*VKORC1 polymorphisms were in Hardy-Weinberg equilibrium for all three race groups examined (ie, Caucasians, African Americans and East Asians), and the observed allele frequencies within each race group were consistent with previously published findings (online [supplementary table 1](#SP1)supplementary table 1).[11](#R11)^11^11\n\n[heartjnl-2016-310901supp001.pdf](/articles/instance/5749368/bin/heartjnl-2016-310901supp001.pdf)heartjnl-2016-310901supp001.pdf^ (231.1KB, pdf) ^ (231.1KB, pdf)\n\nOut of the 8292 patients in Hokusai VTE, 3956 (47.7%) participants (1978 from each treatment group) received \u22651 dose of the study drug, consented to be included in the pharmacogenetic analysis and provided a pharmacogenetic sample and were therefore included in the present analysis.",
                    "In addition, warfarin-associated major bleeding during the first 90 days was lower than what was observed in the pharmacogenetics subanalysis of ENGAGE AF-TIMI 48.[13](#R13)^13^13 The lack of a significant interaction between the bleeding risk associated with warfarin versus edoxaban as a function of warfarin sensitivity may be due to the lower number of patients included in this analysis compared with the ENGAGE AF-TIMI 48 pharmacogenetic analysis.[13](#R13)^13^13 Although the FDA recommends dose adjustments for warfarin in patients with warfarin-sensitive genotypes,[15](#R15)^15^15 in clinical practice, *CYP2C9*CYP2C9 and *VKORC1*VKORC1 genotypes are not routinely assessed, and it has never been demonstrated that genotyping can reduce the risk of bleeding.",
                    "**Conclusion:** \nIn this study, CYP2C9 and VKORC1 genotypes identified patients with VTE at increased bleeding risk with warfarin."
                ]
            }
        ]
    }
}